it is a small molecule inhibitor of the tyrosine kinases c met and vegfr2 and also inhibits axl and ret it was discovered and developed by exelixis inc in 2012 cabozantinib in its capsule formulation was approved by the u s fda under the name cometriq for treating patients with medullary thyroid cancer the capsule form was approved in europe for the same purpose in 2014 in april 2016 the us fda granted approval for marketing the tablet formulation as a second line treatment for kidney cancer and the same was approved in europe in october of that year cabozantinib is used in two forms a capsule form is used since 2012 to treat medullary thyroid cancer and a tablet form is used since 2016 as a second line treatment for renal cell carcinoma cabozantinib has not been tested in pregnant women it causes harm to fetuses in rodents pregnant women should not take this drug and women should not become pregnant while taking it it is not known if cabozantinib is excreted in breast milk the drug should be used with caution in people with a history of heart rhythm problems including long qt interval in the us the